Hero image

COLLABORATIVE WORKING

MSD supports and partners with the NHS and healthcare organisations in a number of different ways.

Through a combination of Collaborative Working (multi-organisation) and Joint Working (direct to NHS provider partnering) we pool skills, experience and resources for the development and implementation of patient-centered projects. Our ability to continue with our long-standing collaborative efforts pivots on the Department of Health's joint working mandate and enables us to discover and invent new ways, every day, to help patients, their families and their loved ones.

Select a project below to see more about how we partner or to find out more please contact us.

MSD COLLABORATIONS

Collaborative Working Projects

Royal Liverpool University Hospital NHS Foundation Trust Pathway Development Project (PDP)

Project Title

Royal Liverpool University Hospital NHS Foundation Trust Pathway Development Project (PDP)

Organisations involved

MSD

Royal Liverpool University Hospital NHS Foundation Trust

Summary

A head and neck Best Practice Timed Pathway has been created with the intention of improving patient experience through promoting quality cancer care and ensuring all head and neck patients receive optimal cancer care. There is an opportunity in the Merseyside area to optimise the head and neck pathway in line with the head and neck Best Practice Timed Pathway to improve the service quality, service efficiency, productivity and patient experience. The desired outcome of this project is an improved head and neck pathway aligned with the Best Practice Timed Pathway and achievement of the head and neck 31 and 62 day Cancer Waiting Time Targets. The project intends to begin on 27th of September 2022 and anticipates a finish date on 26th March 2023

Project Objectives

The primary objective of this project is the optimisation of head and neck pathways across Merseyside. Specifically contributing towards; –

  • An optimised head and neck pathway aligned to the head and neck Best Practice Timed Pathway
  • Achievement of the head and neck Best Practice Timed Pathway, through improved biomarker request turnaround time, the 31-day treatment target and 62 day referral to treatment Cancer Waiting Time targets

Project Approach

  • Pathway mapping of each head and neck service in Merseyside and creation of Lucid charts depicting the current pathway
  • Gap analysis contributing towards co-creation of service re-design plans from gap analysis outputs for each site managing head and neck patients in Merseyside
  • Implementation of an optimised pathway for each site managing head and neck patients across Both parties commit to measuring the outcomes of the project and disseminating these outcomes within 6 months of the project completion

Benefits

Patient Benefits

  • An improved patient experience of the head and neck pathway in
  • Quicker diagnosis and treatment of head and neck and hence improving the chance of successful treatment

NHS Benefits

An optimised pathway in head and neck across Merseyside hospital sites resulting in

  • Achievement of the head and neck 31-day treatment target and 62 day referral to treatment Cancer Waiting Time targets
  • Earlier referral, diagnosis and treatment of head and neck patients
  • Increase in treatment rates for head and neck
  • Optimisation of service delivery

MSD Benefits

  • Better understanding of head and neck patient needs
  • Enhanced reputation of MSD through partnership work
  • As a pharmaceutical manufacturer of oncology medicines, an indirect result of an improved pathway may be that MSD see more appropriate usage of their NICE/SMC approved medicines

Funding

Total Project = £3731.30; MSD contribution = £1540; NHS Contribution = £ 2191.30

 

Job Code: GB-NON-06319 Date of Prep: August 2022


GM Cancer Alliance - MDT Reform Implementation project

Project Title

GM Cancer Alliance – MDT Reform Implementation project

Organisations involved

GM Cancer Alliance

MSD UK Ltd

Summary

The project will provide project management support for a maximum of 6 months to support the implementation of the Greater Manchester (GM) Multi-Disciplinary Team (MDT) standards across Greater Manchester, but with a stronger focus on the NCA (Northern Care Alliance) which has the larger number of trusts, and to implement these standards into the annual quality assurance process. The standards have been developed by GM Cancer Alliance, as part of an eighteen-month MDT Reform project which ended March 2022. The project aimed to drive forward National recommendations and guidance for GM and East Cheshire (EC) cancer MDTs to deliver an improved process, ensuring streamlined processes and standards of care pathways are developed and implemented to make the best use of clinical time and resources and thus improve effectiveness.

Additionally, an MDT toolkit will be developed, to be utilised by MDTs to share best practice and advice on how best to achieve the GM MDT standards. The toolkit will include examples linked to the following improvements that have been identified throughout the project and which will form part of the GM MDT standards: Standardised referral forms, streamlining patients for discussion and outlining pre-triage meetings

As a result of this project, patients may benefit from an accelerated review through the MDT or outside an MDT, using pre-agreed protocols for those less urgent or severe cases, and as a result, treatment decisions are likely to be made earlier than in current practice, thus facilitating accelerated treatment timelines, less anxiety for patients waiting for this decision, and potentially patients deemed as fit for additional treatment giving patients more options.

Outcomes of the collaborative working project will be published within six months of project completion.

Background

MDTs were introduced in the late 1990s and early 2000s in the NHS with the purpose to increase evidence-based practice and prevent implementation of treatments outside of accepted standards. MDTs are considered the gold standard for cancer patient management and mandated by the National Cancer Plan in 2000; with the pledge that all patients with cancer have their care reviewed by an MDT. However, the health services have changed significantly since their introduction and MDTs have come under increasing pressure due to:

  • Significant increases in caseload
  • A change in case-mix including patients with greater comorbidities as a result of an ageing population and increasing number of complex treatment options
  • Increase in numbers and/or complexity of cases to be discussed has not been matched by any increase in time set aside for the MDT
  • Some MDT meetings are sometimes poorly attended by individuals, others by speciality expertise, and there are issues relating to consistent, reliable information technology, data collection and infrastructure such as videoconferencing

Following completion of the MDT reform project, and launch of the regional standards in March 2022, GM Cancer Alliance require project management resource to support the implementation of the GM MDT standards, and to implement these standards into the Trusts annual quality assurance process.

Project Approach

To provide project management for a period of six months to support in the implementation of the GM MDT standards into the Trusts annual quality assurance process. This will involve a project manager from MSD working with GM Cancer Alliance and the local Trusts to create a toolkit and implement the required standard including GMs own Patient Impact Statement.

Data generated by the project will be controlled and processed by NHS only. Only anonymised and aggregated data will be made available to MSD for the purpose of the reporting of the evaluation progress and release of milestone reports.

Project Objectives

  • Creation of a Toolkit to instruct, support and inform Trusts wishing to streamline their own MDTs
  • Process in place to ensure Pre-MDT triage meeting occurs
  • Each MDT to utilise the GM Patient Impact Statement resource to ensure the patient voice is factored into MDT discussions and decision making
  • Each MDT to have established clear lines of responsibility to inform patients of MDT decision
  • Implementation of GM Cancer patient resources to support patient understanding of MDT process and their cancer journey
  • GM MDT standards to be included into Trusts annual quality assurance process

Benefits

Benefits Realisation
Benefits/ Impact to Patients
  • Treatment decision in a shorter timeframe, which may give access to wider treatment options
  • Reducing the pathway time duration
  • Improved patient experience
Benefits to the NHS partner
  • Work more efficiently to address capacity challenges and reduce backlogs
  • More time to devote to more complex patients
  • More appropriate patients reaching a broader treatment decision
Benefits to MSD
  • Supporting our NHS collaborators in the early identification of patients suitable for treatment
  • Deeper understanding of MDT processes and decision making
  • Development of relationships with key clinical leads

 Funding

 MSD Contribution – £19,350; NHS Contribution – £10,755; Total Project – £30,105

 

Job Code GB-NON-06306  Date Of Prep – August 2022

 


Nottingham University Hospital NHS Trust Pathway Development Project (PDP)

Project Title

Nottingham University Hospital NHS Trust Pathway Development Project (PDP)

Organisations involved

MSD
Nottingham University NHS Trust

Summary

A national optimal lung cancer pathway has been created with the intention of improving patient experience through promoting quality cancer care and ensuring all lung cancer patients receive optimal cancer care. There is an opportunity in Nottingham to optimise the lung cancer pathway in line with the national optimal lung cancer pathway to improve the service quality, service efficiency, productivity and patient experience. The desired outcome of this project is an improved lung cancer pathway aligned with the national optimal lung cancer pathway and achievement of the lung cancer 28 day Faster Diagnostic Standard and the 31 and 62 day Cancer Waiting Time Targets. The project intends to begin on 25th July 2022 and anticipates a finish date on 30th November 2022.

Project Objectives

The primary objective of this project is the optimisation of lung cancer pathways across Nottingham. Specifically contributing towards; –

  • An optimised lung cancer pathway aligned to the national optimal timed lung cancer here pathway
  • Achievement of the lung cancer 28 day Faster Diagnostic Standard, 31-day treatment target and 62 day referral to treatment Cancer Waiting Time targets

Project Approach

  • Pathway mapping of each lung cancer service in Nottingham and creation of Lucid charts depicting the current pathway
  • Gap analysis contributing towards co-creation of service re-design plans from gap analysis outputs for each site managing lung cancer patients in Nottingham
  • Implementation of an optimised pathway for each site managing lung cancer patients across Nottingham
  • Both parties commit to measuring the outcomes of the project and disseminating these outcomes within 6 months of the project completion

Benefits

Patient Benefits

  • An improved patient experience of the lung cancer pathway in Nottingham
  • Quicker diagnosis and treatment of lung cancer and hence improving the chance of successful treatment

NHS Benefits

An optimised pathway in lung cancer across Nottingham hospital sites resulting in:

  • Achievement of the lung cancer here 28 day Faster Diagnostic Standard, 31-day treatment target and 62 day referral to treatment Cancer Waiting Time targets
  • Earlier referral, diagnosis and treatment of lung cancer patients
  • Increase in treatment rates for lung cancer
  • Optimisation of service delivery

MSD Benefits

  • Better understanding of lung cancer patient needs
  • Enhanced reputation of MSD through partnership work
  • As a pharmaceutical manufacturer of oncology medicines, an indirect result of an improved pathway may be that MSD see more appropriate usage of their NICE/SMC approved medicines

Funding

Total Project = £4,529; MSD contribution = £3,100; NHS Contribution = £1,429

 

Job Code GB-NON-05520. Date of Preparation – March 2022


Renal Cell Carcinoma Southern Health and Social Care Trust Pathway Development Project (PDP)

Project Title

Renal Cell Carcinoma Southern Health and Social Care Trust Pathway Development Project (PDP)

Organisations involved

MSD

Southern Health and Social Care Trust

Summary

A Renal Cell Carcinoma pathway has been created with the intention of improving patient experience through promoting quality cancer care and ensuring all renal cell carcinoma patients receive optimal cancer care. There is an opportunity in Southern Health and Social Care Trust to optimise the renal cell carcinoma pathway to improve the service quality, service efficiency, productivity and patient experience. The desired outcome of this project is an improved renal cell carcinoma pathway and achievement of the renal cell carcinoma 31-day and 62-day Cancer Waiting Time Targets. The project intends to begin on 01/07/22 and anticipates a finish date on 31/03/23.

Project Objectives

The primary objective of this project is the optimisation of renal cell carcinoma pathways across Southern Health and Social Care Trust. Specifically contributing towards; –

  • An optimised renal cell carcinoma pathway
  • Achievement of the renal cell carcinoma 31-day treatment target and 62-day referral to treatment Cancer Waiting Time targets

Project Approach

  • Pathway mapping of each renal cell carcinoma service in Southern Health and Social Care Trust and creation of Lucid charts depicting the current pathway
  • Gap analysis contributing towards co-creation of service re-design plans from gap analysis outputs for each site managing renal cell carcinoma patients in Southern Health and Social Care Trust
  • Implementation of an optimised pathway for each site managing renal cell carcinoma patients across Southern Health and Social Care Trust
  • Both parties commit to measuring the outcomes of the project and disseminating these outcomes within 6 months of the project completion

Benefits

Patient Benefits

  • An improved patient experience of the renal cell carcinoma pathway in Southern Health and Social Care Trust.
  • Quicker diagnosis and treatment of renal cell carcinoma and hence improving the chance of successful treatment

NHS Benefits

An optimised pathway in renal cell carcinoma across Southern Health and Social Care Trust hospital sites resulting in:

  • Achievement of the Renal Cell Carcinoma 31-day treatment target and 62-day referral to treatment Cancer Waiting Time targets
  • Earlier referral, diagnosis and treatment of renal cell carcinoma patients
  • Increase in treatment rates for renal cell carcinoma
  • Optimisation of service delivery

MSD Benefits

  • Better understanding of renal cell carcinoma patient needs
  • Enhanced reputation of MSD through partnership work
  • As a pharmaceutical manufacturer of oncology medicines, an indirect result of an improved pathway may be that MSD see more appropriate usage of their NICE/SMC approved medicines

Funding

Total Project = £6020.48; MSD contribution = £3100; NHS Contribution = £2920.48

 

 

Job Code GB-NON-06125. Date of Preparation – June 2022


Renal Cell Carcinoma Belfast Health and Social Care Trust Pathway Development Project (PDP)

Project Title

Renal Cell Carcinoma Belfast Health and Social Care Trust Pathway Development Project (PDP)

Organisations involved

MSD

Belfast Health and Social Care Trust

Summary

A Renal Cell Carcinoma pathway has been created with the intention of improving patient experience through promoting quality cancer care and ensuring all renal cell carcinoma patients receive optimal cancer care. There is an opportunity in Belfast Health and Social Care Trust to optimise the renal cell carcinoma pathway to improve the service quality, service efficiency, productivity and patient experience. The desired outcome of this project is an improved renal cell carcinoma pathway and achievement of the renal cell carcinoma 31-day and 62-day Cancer Waiting Time Targets. The project intends to begin on 01/07/22 and anticipates a finish date on 31/03/23.

Project Objectives

The primary objective of this project is the optimisation of renal cell carcinoma pathways across Belfast Health and Social Care Trust. Specifically contributing towards;

  • An optimised renal cell carcinoma pathway
  • Achievement of the renal cell carcinoma 31-day treatment target and 62-day referral to treatment Cancer Waiting Time targets

Project Approach

  • Pathway mapping of each renal cell carcinoma service in Belfast Health and Social Care Trust and creation of Lucid charts depicting the current pathway
  • Gap analysis contributing towards co-creation of service re-design plans from gap analysis outputs for each site managing renal cell carcinoma patients in Belfast Health and Social Care Trust
  • Implementation of an optimised pathway for each site managing renal cell carcinoma patients across Belfast Health and Social Care Trust
  • Both parties commit to measuring the outcomes of the project and disseminating these outcomes within 6 months of the project completion

Benefits

Patient Benefits

  • An improved patient experience of the renal cell carcinoma pathway in Belfast Health and Social Care Trust
  • Quicker diagnosis and treatment of renal cell carcinoma and hence improving the chance of successful treatment

NHS Benefits

An optimised pathway in renal cell carcinoma across Belfast Health and Social Care Trust hospital sites resulting in:

  • Achievement of the Renal Cell Carcinoma 31-day treatment target and 62-day referral to treatment Cancer Waiting Time targets
  • Earlier referral, diagnosis and treatment of renal cell carcinoma patients
  • Increase in treatment rates for renal cell carcinoma
  • Optimisation of service delivery

MSD Benefits

  • Better understanding of renal cell carcinoma patient needs
  • Enhanced reputation of MSD through partnership work
  • As a pharmaceutical manufacturer of oncology medicines, an indirect result of an improved pathway may be that MSD see more appropriate usage of their NICE/SMC approved medicines

Funding

Total Project = £8099.42; MSD contribution = £4300; NHS Contribution = £3799.42

 

Job Code GB-NON-06011. Date of Preparation – June 2022


Glasgow Royal Infirmary Pathway Development Project (PDP)

Project Title

Glasgow Royal Infirmary Pathway Development Project (PDP)

Organisations involved

MSD

Glasgow Royal Infirmary

Summary

There is an opportunity in the North Sector of NHS Greater Glasgow to optimise the lung cancer pathway   to improve the service quality, service efficiency, productivity and patient experience. The desired outcome of this project is an improved  lung cancer pathway and achievement of the lung cancer  31 and 62 day Cancer Waiting Time Targets. The project intends to begin on 01/06/2022 and anticipates a finish date on 30/11/2022

Project Objectives

The primary objective of this project is the optimisation of lung cancer pathways across North Sector of Glasgow. Specifically contributing towards; –

  • An optimised lung cancer pathway
  • Achievement of the 31-day treatment target and 62-day referral to treatment lung Cancer Waiting Time targets

Project Approach

  • Pathway mapping of each lung cancer service in North Sector of Greater Glasgow and creation of Lucid charts depicting the current pathway
  • Gap analysis contributing towards co-creation of service re-design plans from gap analysis outputs for each site managing lung cancer patients in North Sector of Greater Glasgow
  • Implementation of an optimised pathway for each site managing lung cancer patients across North Sector of Greater Glasgow
  • Both parties commit to measuring the outcomes of the project and disseminating these outcomes within 6 months of the project completion

Benefits

Patient Benefits

  • An improved patient experience of the lung cancer pathway in North Sector of Greater Glasgow
  • Quicker diagnosis and treatment of lung cancer and hence improving the chance of successful treatment

NHS Benefits

An optimised pathway in lung cancer across North Sector of Greater Glasgow hospital sites resulting in:

  • Achievement of the lung cancer 31-day treatment target and 62-day referral to treatment Cancer Waiting Time targets
  • Earlier referral, diagnosis and treatment of lung cancer patients
  • Increase in treatment rates for lung cancer
  • Optimisation of service delivery

MSD Benefits

  • Better understanding of lung cancer patient needs
  • Enhanced reputation of MSD through partnership work
  • As a pharmaceutical manufacturer of oncology medicines, an indirect result of an improved pathway may be that MSD see more appropriate usage of their NICE/SMC approved medicines

Funding

Total Project = £3,700.00; MSD contribution = £3,688.32; NHS Contribution = £7,388.32

 

Job Code GB-NON-05960. Date of Preparation – May 2022


Hywel Dda University Health Board lung Pathway Development Project (PDP)

Project Title

Hywel Dda University Health Board lung Pathway Development Project (PDP)

Organisations involved

MSD

Hywel Dda University Health Board

Summary

A national optimal lung cancer pathway has been created with the intention of improving patient experience through promoting quality cancer care and ensuring all lung cancer patients receive optimal cancer care. There is an opportunity in Hywel Dda University Health Board to optimise the lung cancer pathway  in line with the national optimal lung cancer pathway to improve the service quality, service efficiency, productivity and patient experience. The desired outcome of this project is an improved lung cancer pathway aligned with the national optimal pathway and achievement of the lung cancer 62 day Cancer Waiting Time Targets. The project intends to begin on 1st April 2022 and anticipates a finish date on 30th September 2022

Project Objectives

The primary objective of this project is the optimisation of lung cancer pathways across Hywel Dda University Health Board. Specifically contributing towards; –

  • An optimised lung cancer pathway aligned to the national optimal timed lung cancer
  • Achievement of the lung cancer 62 day Cancer Waiting Time targets

Project Approach

  • Pathway mapping of each lung cancer service in Hywel Dda University Health Board and creation of Lucid charts depicting the current pathway
  • Gap analysis contributing towards co-creation of service re-design plans from gap analysis outputs for each site managing lung cancer patients in Hywel Dda University Health Board.
  • Implementation of an optimised pathway for each site managing lung cancer patients across Hywel Dda University Health Board.
  • Both parties commit to measuring the outcomes of the project and disseminating these outcomes within 6 months of the project completion

Benefits

Patient Benefits

  • An improved patient experience of the lung cancer pathway in Hywel Dda University Health Board.
  • Quicker diagnosis and treatment of lung cancer and hence improving the chance of successful treatment

NHS Benefits

An optimised pathway in lung cancer across Hywel Dda University Health Board  hospital sites resulting in

  • Achievement of the lung cancer (62 day) Cancer Waiting Time targets
  • Earlier referral, diagnosis and treatment of lung cancer patients
  • Increase in treatment rates for lung cancer
  • Optimisation of service delivery

MSD Benefits

  • Better understanding of lung cancer patient needs
  • Enhanced reputation of MSD through partnership work
  • As a pharmaceutical manufacturer of oncology medicines, an indirect result of an improved pathway may be that MSD see more appropriate usage of their NICE/SMC approved medicines

Funding

Total Project = £4,477.25.10; MSD contribution = £3,100; NHS Contribution = £ 1377.25

 

Job Code GB-NON-05710. Date of Preparation – March 2022


Swansea Bay University Health Board Head & Neck cancer Pathway Development Project (PDP)

Project Title

Swansea Bay University Health Board Head & Neck cancer Pathway Development Project (PDP)

Organisations involved

MSD

Swansea Bay University Health Board

Summary

A national optimal head and neck cancer pathway has been created with the intention of improving patient experience through promoting quality cancer care and ensuring all head and neck cancer patients receive optimal cancer care. There is an opportunity in Swansea Bay University Health Board to optimise the head and neck cancer pathway  in line with the national optimal head and neck cancer pathway to improve the service quality, service efficiency, productivity and patient experience. The desired outcome of this project is an improved  head and neck cancer pathway aligned with the national optimal pathway and achievement of the head and neck cancer  62 day Cancer Waiting Time Targets. The project intends to begin on 15th May 2022 and anticipates a finish date on 30th November 2022

Project Objectives

The primary objective of this project is the optimisation of head and neck cancer pathways across Swansea Bay University Health Board. Specifically contributing towards; –

  • An optimised head and neck cancer pathway aligned to the national optimal timed head and neck cancer
  • Achievement of the head and neck cancer 62 day Cancer Waiting Time targets

Project Approach

  •  Pathway mapping of each head and neck cancer service in Swansea Bay University Health Board and creation of Lucid charts depicting the current pathway
  • Gap analysis contributing towards co-creation of service re-design plans from gap analysis outputs for each site managing head and neck cancer patients in Swansea Bay University Health Board.
  • Implementation of an optimised pathway for each site managing head and neck cancer patients across Swansea Bay University Health Board.
  • Both parties commit to measuring the outcomes of the project and disseminating these outcomes within 6 months of the project completion

Benefits

Patient Benefits

  • An improved patient experience of the head and neck cancer pathway in Swansea Bay University Health Board.
  • Quicker diagnosis and treatment of head and neck cancer and hence improving the chance of successful treatment

NHS Benefits

An optimised pathway in head and neck cancer across Swansea Bay University Health Board  hospital sites resulting in

  • Achievement of the head and neck cancer 62 day) Cancer Waiting Time targets
  • Earlier referral, diagnosis and treatment of head and neck cancer patients
  • Increase in treatment rates for head and neck cancer
  • Optimisation of service delivery

MSD Benefits

  • Better understanding of head and neck cancer patient needs
  • Enhanced reputation of MSD through partnership work
  • As a pharmaceutical manufacturer of oncology medicines, an indirect result of an improved pathway may be that MSD see more appropriate usage of their NICE/SMC approved medicines

Funding

Total Project = £4,944.10; MSD contribution = £3,100.00; NHS Contribution = £ 1844.10

Job Code GB-NON-05954. Date of Preparation – May 2022


Dorset County Hospital NHS FT Head & Neck Pathway Development Project (PDP)

Project Title

Dorset County Hospital NHS FT Head & Neck  Pathway Development Project (PDP)

Organisations involved

MSD

Dorset County Hospital NHS Foundation Trust

Summary

A national optimal head & neck cancer pathway has been created with the intention of improving patient experience through promoting quality cancer care and ensuring all head & neck cancer patients receive optimal cancer care There is an opportunity in Dorset to optimise the head & neck cancer pathway in line with the national optimal head & neck cancer pathway to improve the service quality, service efficiency, productivity and patient experience. The desired outcome of this project is an improved head & neck cancer pathway aligned with the national optimal pathway and achievement of the head & neck cancer 28 day Faster Diagnostic Standard and the 31- and 62-day Cancer Waiting Time Targets. The project intends to begin on 4th March and anticipates a finish date on 30th September 2022.

Project Objectives

The primary objective of this project is the optimisation of head & neck cancer pathways across Dorset. Specifically contributing towards; –

  • An optimised head & neck cancer pathway aligned to the national optimal timed insert cancer here
  • Achievement of the head & neck cancer 28 day Faster Diagnostic Standard, 31-day treatment target and 62 day referral to treatment Cancer Waiting Time targets

Project Approach

  • Pathway mapping of each head & neck cancer service in Dorset and creation of Lucid charts depicting the current pathway
  • Gap analysis contributing towards co-creation of service re-design plans from gap analysis outputs for each site managing head & neck cancer patients in Dorset
  • Implementation of an optimised pathway for each site managing head & neck cancer patients across Dorset
  • Both parties commit to measuring the outcomes of the project and disseminating these outcomes within 6 months of the project completion

Benefits

Patient Benefits

  • An improved patient experience of the head & neck cancer pathway in Dorset
  • Quicker diagnosis and treatment of head & neck cancer and hence improving the chance of successful treatment

NHS Benefits

An optimised pathway in head & neck cancer across Dorset hospital sites resulting in:

  • Achievement of the head & neck cancer, 28 day Faster Diagnostic Standard, 31-day treatment target and 62 day referral to treatment Cancer Waiting Time targets
  • Earlier referral, diagnosis and treatment of head & neck cancer patients
  • Increase in treatment rates for head & neck cancer
  • Optimisation of service delivery

MSD Benefits

  • Better understanding of head & neck cancer patient needs
  • Enhanced reputation of MSD through partnership work
  • As a pharmaceutical manufacturer of oncology medicines, an indirect result of an improved pathway may be that MSD see more appropriate usage of their NICE/SMC approved medicines

Funding

Total Project = £5,916.64 MSD contribution = £2,800.00 NHS Contribution = £ 3,116.64

 

Job Code GB-NON-05686. Date of Preparation – March 2022


Northern Health and Social Care Trust Pathway Development Project (PDP)

Project Title

Northern Health and Social Care Trust Pathway Development Project (PDP)

Organisations involved

MSD

Northern Health and Social Care Trust

Summary

National optimal oesophageal cancer pathways have been created with the intention of improving patient experience through promoting quality cancer care and ensuring all oesophageal cancer patients receive optimal cancer care. There is an opportunity in Northern Health and Social Care Trust to optimise the oesophageal cancer pathway   to improve the service quality, service efficiency, productivity and patient experience. The desired outcome of this project is an improved  oesophageal cancer pathway  and achievement of the oesophageal cancer   31 and 62 day Cancer Waiting Time Targets. The project intends to begin on 04/05/22 and anticipates a finish date on 31/12/22

Project Objectives

The primary objective of this project is the optimisation of oesophageal cancer pathways across Northern Health and Social Care Trust. Specifically contributing towards; –

  • An optimised oesophageal cancer pathway
  • Achievement of the oesophageal cancer 31-day treatment target and 62-day referral to treatment Cancer Waiting Time targets

Project Approach

  • Pathway mapping of each oesophageal cancer service in Northern Health and Social Care Trust and creation of Lucid charts depicting the current pathway
  • Gap analysis contributing towards co-creation of service re-design plans from gap analysis outputs for each site managing oesophageal cancer patients in Northern Health and Social Care Trust
  • Implementation of an optimised pathway for each site managing oesophageal cancer patients across Northern Health and Social Care Trust
  • Both parties commit to measuring the outcomes of the project and disseminating these outcomes within 6 months of the project completion

Benefits

Patient Benefits

  • An improved patient experience of the oesophageal cancer pathway in Northern Health and Social Care Trust.
  • Quicker diagnosis and treatment of oesophageal cancer and hence improving the chance of successful treatment

NHS Benefits

An optimised pathway in oesophageal cancer across Northern Health and Social Care Trust  hospital sites resulting in

  • Achievement of the oesophageal cancer 31-day treatment target and 62 day referral to treatment Cancer Waiting Time targets
  • Earlier referral, diagnosis and treatment of oesophageal cancer patients
  • Increase in treatment rates for oesophageal cancer
  • Optimisation of service delivery

MSD Benefits

  • Better understanding of oesophageal cancer patient needs
  • Enhanced reputation of MSD through partnership work
  • As a pharmaceutical manufacturer of oncology medicines, an indirect result of an improved pathway may be that MSD see more appropriate usage of their NICE/SMC approved medicines

Funding

Total Project = £4558.26 MSD contribution = £2500.00 NHS Contribution = £2058.26

 

Job Code GB-NON-05929. Date of Preparation – May 2022


Belfast Health and Social Care Trust Pathway Development Project (PDP)

Project Title

Belfast Health and Social Care Trust Pathway Development Project (PDP)

Organisations involved

MSD

Belfast Health and Social Care Trust

Summary

A national optimal Oesophageal Cancer pathway has been created with the intention of improving patient experience through promoting quality cancer care and ensuring all Oesophageal Cancer patients receive optimal cancer care. There is an opportunity in Belfast Health and Social Care Trust to optimise the oesophageal cancer pathway to improve the service quality, service efficiency, productivity and patient experience. The desired outcome of this project is an improved oesophageal cancer pathway and achievement of the Oesophageal Cancer the 31 and 62 day Cancer Waiting Time Targets. The project intends to begin on 20/04/22 and anticipates a finish date on 31/12/22

Project Objectives

The primary objective of this project is the optimisation of oesophageal cancer pathways across Belfast Health and Social Care Trust. Specifically contributing towards; –

  • An optimised oesophageal cancer pathway
  • Achievement of the Oesophageal Cancer 31-day treatment target and 62-day referral to treatment Cancer Waiting Time targets

Project Approach

  • Pathway mapping of each oesophageal cancer service in Belfast Health and Social Care Trust and creation of Lucid charts depicting the current pathway
  • Gap analysis contributing towards co-creation of service re-design plans from gap analysis outputs for each site managing oesophageal cancer patients in Belfast Health and Social Care Trust
  • Implementation of an optimised pathway for each site managing oesophageal cancer patients across Belfast Health and Social Care Trust
  • Both parties commit to measuring the outcomes of the project and disseminating these outcomes within 6 months of the project completion

Benefits

Patient Benefits

  • An improved patient experience of the oesophageal cancer pathway in Belfast Health and Social Care Trust.
  • Quicker diagnosis and treatment of oesophageal cancer and hence improving the chance of successful treatment

NHS Benefits

An optimised pathway in oesophageal cancer across Belfast Health and Social Care Trust hospital sites resulting in:

  • Achievement of the Oesophageal Cancer 31-day treatment target and 62-day referral to treatment Cancer Waiting Time targets
  • Earlier referral, diagnosis and treatment of oesophageal cancer patients
  • Increase in treatment rates for oesophageal cancer
  • Optimisation of service delivery

MSD Benefits

  • Better understanding of oesophageal cancer patient needs
  • Enhanced reputation of MSD through partnership work
  • As a pharmaceutical manufacturer of oncology medicines, an indirect result of an improved pathway may be that MSD see more appropriate usage of their NICE/SMC approved medicines

Funding

Total Project = £9631.26; MSD contribution = £4900.00; NHS Contribution = £ 4731.26

 

Job Code GB-NON-05882. Date of Preparation – April 2022


Southern Health and Social Care Trust Pathway Development Project (PDP)

Project Title

Southern Health and Social Care Trust Pathway Development Project (PDP)

Organisations involved

MSD

Southern Health and Social Care Trust

Summary

National optimal oesophageal cancer pathways have been created with the intention of improving patient experience through promoting quality cancer care and ensuring all oesophageal cancer patients receive optimal cancer care. There is an opportunity in Southern Health and Social Care Trust to optimise the oesophageal cancer pathway to improve the service quality, service efficiency, productivity and patient experience. The desired outcome of this project is an improved  oesophageal cancer pathway  and achievement of the Oesophageal Cancer   31 and 62 day Cancer Waiting Time Targets. The project intends to begin on 20/04/22 and anticipates a finish date on 31/12/22.

Project Objectives 

The primary objective of this project is the optimisation of oesophageal cancer pathways across Southern Health and Social Care Trust. Specifically contributing towards; –

  • An optimised oesophageal cancer pathway
  • Achievement of the Oesophageal Cancer 31-day treatment target and 62-day referral to treatment Cancer Waiting Time targets

Project Approach

  • Pathway mapping of each oesophageal cancer service in Southern Health and Social Care Trust and creation of Lucid charts depicting the current pathway
  • Gap analysis contributing towards co-creation of service re-design plans from gap analysis outputs for each site managing oesophageal cancer patients in Southern Health and Social Care Trust
  • Implementation of an optimised pathway for each site managing oesophageal cancer patients across Southern Health and Social Care Trust
  • Both parties commit to measuring the outcomes of the project and disseminating these outcomes within 6 months of the project completion

Benefits

Patient Benefits

  • An improved patient experience of the oesophageal cancer pathway in Southern Health and Social Care Trust
  • Quicker diagnosis and treatment of oesophageal cancer and hence improving the chance of successful treatment

NHS Benefits

An optimised pathway in oesophageal cancer across Southern Health and Social Care Trust hospital sites resulting in:

  • Achievement of the Oesophageal Cancer 31-day treatment target and 62 day referral to treatment Cancer Waiting Time targets
  • Earlier referral, diagnosis and treatment of oesophageal cancer patients
  • Increase in treatment rates for oesophageal cancer
  • Optimisation of service delivery

MSD Benefits

  • Better understanding of oesophageal cancer patient needs
  • Enhanced reputation of MSD through partnership work
  • As a pharmaceutical manufacturer of oncology medicines, an indirect result of an improved pathway may be that MSD see more appropriate usage of their NICE/SMC approved medicines

Funding

Total Project = £6020.48; MSD contribution = £3100; NHS Contribution = £2920.48

 

Job Code GB-NON-05884. Date of Preparation – April 2022


Belfast Health and Social Care Trust Pathway Development Project (PDP)

Project Title

Belfast Health and Social Care Trust Pathway Development Project (PDP)

Organisations involved

MSD

Belfast Health and Social Care Trust

Summary

A national optimal lung cancer pathway has been created with the intention of improving patient experience through promoting quality cancer care and ensuring all lung cancer patients receive optimal cancer care. There is an opportunity in Belfast Health and Social Care Trust to optimise the lung cancer pathway   to improve the service quality, service efficiency, productivity and patient experience. The desired outcome of this project is an improved  lung cancer pathway  and achievement of the Lung Cancer   the 31 and 62 day Cancer Waiting Time Targets. The project intends to begin on 14/03/22 and anticipates a finish date on 01/12/22.

 Project Objectives 

The primary objective of this project is the optimisation of lung cancer pathways across Belfast Health and Social Care Trust. Specifically contributing towards; –

  • An optimised lung cancer pathway
  • Achievement of the Lung Cancer 31-day treatment target and 62 day referral to treatment Cancer Waiting Time targets

Project Approach

  • Pathway mapping of each lung cancer service in Belfast Health and Social Care Trust and creation of Lucid charts depicting the current pathway
  • Gap analysis contributing towards co-creation of service re-design plans from gap analysis outputs for each site managing lung cancer patients in Belfast Health and Social Care Trust
  • Implementation of an optimised pathway for each site managing lung cancer patients across Belfast Health and Social Care Trust
  • Both parties commit to measuring the outcomes of the project and disseminating these outcomes within 6 months of the project completion

Benefits

Patient Benefits

  • An improved patient experience of the lung cancer pathway in Belfast Health and Social Care Trust
  • Quicker diagnosis and treatment of lung cancer and hence improving the chance of successful treatment

NHS Benefits

An optimised pathway in lung cancer across Belfast Health and Social Care Trust  hospital sites resulting in:

  • Achievement of the lung cancer 31-day treatment target and 62 day referral to treatment Cancer Waiting Time targets
  • Earlier referral, diagnosis and treatment of lung cancer patients
  • Increase in treatment rates for lung cancer
  • Optimisation of service delivery

MSD Benefits

  • Better understanding of lung cancer patient needs
  • Enhanced reputation of MSD through partnership work
  • As a pharmaceutical manufacturer of oncology medicines, an indirect result of an improved pathway may be that MSD see more appropriate usage of their NICE/SMC approved medicines

Funding

Total Project = £7076.67; MSD contribution = £3700; NHS Contribution = £ 3376.67

 

Job Code GB-NON-05650. Date of Preparation – March 2022


Oxford Respiratory Early Diagnosis Service (REDS) Lung Cancer Pathway Development Project (PDP)

Project Title

Oxford Respiratory Early Diagnosis Service (REDS) Lung Cancer Pathway Development Project (PDP)

Organisations involved

MSD

Oxford University NHS Hospitals Trust

Summary

A national optimal lung cancer pathway has been created with the intention of improving patient experience through promoting quality cancer care and ensuring all lung cancer patients receive optimal care. There is an opportunity in Oxfordshire to optimise the lung cancer pathway in line with the national optimal lung cancer pathway to improve the service quality, service efficiency, productivity and patient experience. The desired outcome of this project is an improved lung cancer pathway aligned with the national optimal pathway and achievement of the lung cancer 28 day Faster Diagnostic Standard and the 31 and 62 day Cancer Waiting Time Targets. The project intends to begin on 6th October 2020 and anticipates a finish date on 4th July 2022

Project Objectives

The primary objective of this project is the optimisation of lung cancer pathways across Oxfordshire. Specifically contributing towards; –

  • An optimised lung cancer pathway, aligned to the national optimal timed lung cancer pathway
  • Achievement of the lung cancer 28 day Faster Diagnostic Standard, 31-day treatment target and 62 day referral to treatment Cancer Waiting Time target

Project Approach

  • Pathway mapping of each lung cancer service in Oxfordshire and creation of Lucid charts depicting the current pathway
  • Gap analysis contributing towards co-creation of service re-design plans from gap analysis outputs for each site managing lung cancer patients in Oxfordshire
  • Implementation of an optimised pathway for each site managing lung cancer patients across Oxfordshire
  • Both parties commit to measuring the outcomes of the project and disseminating these outcomes within 6 months of the project completion

Benefits

Patient Benefits

  • An improved patient experience of the lung cancer pathway in Oxfordshire.
  • Quicker diagnosis and treatment of lung cancer and hence improving the chance of successful treatment

NHS Benefits

An optimised pathway in lung cancer across Oxfordshire hospital sites resulting in

  • Achievement of the lung cancer 28 day Faster Diagnostic Standard, 31 day treatment target and 62 day referral to treatment target
  • Earlier referral, diagnosis and treatment of lung cancer patients
  • Increase in treatment rates for lung cancer
  • Optimisation of service delivery

MSD Benefits

  • Better understanding of lung cancer patient needs
  • Enhanced reputation of MSD through partnership work
  • As a pharmaceutical manufacturer of oncology medicines, an indirect result of an improved pathway may be that MSD see more appropriate usage of their NICE/SMC approved medicines

Funding

Total Project = £16,786 MSD contribution = £5,140  NHS Contribution = £11,646

 

Job Code GB-NON-05370. Date of Preparation – December 2021


Aneurin Bevan University Health Board Head & Neck Pathway Development Project (PDP)

Project Title

Aneurin Bevan University Health Board head and neck Pathway Development Project (PDP)

Organisations involved

MSD

Aneurin Bevan University Health Board

Summary

A national optimal head and neck Cancer pathway has been created with the intention of improving patient experience through promoting quality cancer care and ensuring all head and neck cancer patients receive optimal cancer care. There is an opportunity in Aneurin Bevan University Health Board to optimise the head and neck cancer pathway  in line with the National Optimal Pathway for head and neck cancer to improve the service quality, service efficiency, productivity and patient experience. The desired outcome of this project is an improved  head and neck cancer pathway aligned with the national optimal pathway and achievement of the head and neck cancer  62 day Cancer Waiting Time Targets. The project intends to begin on 15th February 2022 and anticipates a finish date on 31st May 2022.

Project Objectives

The primary objective of this project is the optimisation of head and neck cancer pathways across Aneurin Bevan University Health Board. Specifically contributing towards; –

  • An optimised head and neck cancer pathway aligned to the national optimal timed head and neck cancer
  • Achievement of the head and neck cancer 62 day Cancer Waiting Time targets

Project Approach

  • Pathway mapping of each head and neck cancer service in Aneurin Bevan University Health Board and creation of Lucid charts depicting the current pathway
  • Gap analysis contributing towards co-creation of service re-design plans from gap analysis outputs for each site managing head and neck cancer patients in Aneurin Bevan University Health Board
  • Implementation of an optimised pathway for each site managing head and neck cancer patients across Aneurin Bevan University Health Board
  • Both parties commit to measuring the outcomes of the project and disseminating these outcomes within 6 months of the project completion

Benefits

Patient Benefits

  • An improved patient experience of the head and neck cancer pathway in Aneurin Bevan University Health Board
  • Quicker diagnosis and treatment of head and neck cancer and hence improving the chance of successful treatment

NHS Benefits

An optimised pathway in head and neck cancer across Aneurin Bevan University Health Board  hospital sites resulting in

  • Achievement of the head and neck canceri 62 day) Cancer Waiting Time targets
  • Earlier referral, diagnosis and treatment of head and neck cancer patients
  • Increase in treatment rates for head and neck cancer
  • Optimisation of service delivery

MSD Benefits

  • Better understanding of head and neck cancer patient needs
  • Enhanced reputation of MSD through partnership work
  • As a pharmaceutical manufacturer of oncology medicines, an indirect result of an improved pathway may be that MSD see more appropriate usage of their NICE/SMC approved medicines

Funding

Total Project = £4344.10; MSD contribution = £2500; NHS Contribution = £ 1844.10

 

Job Code GB-NON-05533. Date of Preparation– February 2022


University Hospitals of Birmingham (UHB) Lung Cancer Pathway Development Project (PDP)

Project Title

University Hospitals of Birmingham (UHB) Lung Cancer Pathway Development Project (PDP)

Organisations involved

MSD

University Hospitals Birmingham Foundation Trust (UHB), West Birmingham & Sandwell Foundation Trust, Walsall Foundation Trust, Birmingham & Solihull Integrated Care System (BSOL ICS), Birmingham Health Partners (BHP), Black Country & West Birmingham Strategic Transformational Partnership (BC & WB STP) & West Midlands Cancer Alliance

Summary

A national optimal lung pathway has been created with the intention of improving patient experience through promoting quality cancer care and ensuring all lung cancer patients receive optimal cancer care.  There is an opportunity in Birmingham and the referring trusts of the West Midlands to optimise the lung cancer pathway in line with the national optimal lung cancer pathway to improve the service quality, service efficiency, productivity and patient experience. The desired outcome of this project is an improved  lung cancer pathway aligned with the national optimal lung cancer pathway and achievement of the lung cancer  28 day Faster Diagnostic Standard, the 31,  62  and 104 day Cancer Waiting Time Targets. The project intends to begin on 1st January 2022 and anticipates a finish date on 30th April 2022.

Project Objectives

The primary objective of this project is the optimisation of lung cancer pathways across Birmingham and referring centres across the West Midlands. Specifically contributing towards; –

  • An optimised lung cancer pathway aligned to the national optimal lung cancer pathway
  • Achievement of the lung cancer 28 day Faster Diagnostic Standard, 31-day treatment target, 62-day referral to treatment and 104-day Cancer Waiting Time targets

Project Approach

  • Pathway mapping of each point of entry to the lung cancer service in Birmingham as well as referring centres from across the West Midlands and creation of Lucid charts depicting the current pathway
  • Gap analysis contributing towards co-creation of service re-design plans from gap analysis outputs for each site managing lung cancer patients in UHB
  • Implementation of an optimised pathway for each site managing lung cancer patients across Birmingham as well as those referred into UHB from across the West Midlands
  • Both parties commit to measuring the outcomes of the project and disseminating these outcomes within 6 months of the project completion

Benefits

Patient Benefits

  • An improved patient experience of the lung cancer pathway in Birmingham and referring centres across the West Midlands.
  • Quicker diagnosis and treatment of lung cancer and hence improving the chance of successful treatment

NHS Benefits

An optimised pathway in lung cancer across UHB hospital sites resulting in

  • Achievement of the 28 day Faster Diagnostic Standard, 31-day treatment target, 62-day referral to treatment and 104 day Cancer Waiting Time targets
  • Earlier referral, diagnosis and treatment of lung cancer patients
  • Increase in treatment rates for lung cancer
  • Optimisation of service delivery

MSD Benefits

  • Better understanding of lung cancer patient needs
  • Enhanced reputation of MSD through partnership work
  • As a pharmaceutical manufacturer of oncology medicines, an indirect result of an improved pathway may be that MSD see more appropriate usage of their NICE/SMC approved medicines

Funding

Total Project = £16,471.31; MSD contribution = £9,700.00; NHS Contribution = £ 6,771.31

 

Job Code GB-NON-05402. Date of Preparation – December 2021


Salisbury Lung Cancer Prehabilitation Pathway Development Project (PDP)

Project Title

Salisbury Lung Cancer Prehabilitation Pathway Development Project (PDP)

Organisations involved

MSD

Salisbury Hospital NHS Foundation Trust

Summary

A national optional lung cancer pathway has been created with the intention of improving patient experience through promoting quality cancer care and ensuring all lung cancer patients receive optimal cancer care. There is an opportunity in Wiltshire to optimise the lung cancer pathway in line with the national optimal lung cancer pathway to improve the service quality, service efficiency, productivity and patient experience. The desired outcome of this project is an improved lung cancer pathway aligned with the national optimal pathway and achievement of the lung Cancer Waiting Time Targets. The project intends to begin on 5th May 2021 and anticipates a finish date on 4th July 2022

Project Objectives

The primary objective of this project is the optimisation of lung cancer pathways across Wiltshire. Specifically contributing towards; –

  • An optimised lung cancer pathway, aligned to the national optimal timed lung cancer pathway
  • Achievement of the lung cancer 28 day Faster Diagnostic Standard, 31-day treatment target and 62 day referral to treatment Cancer Waiting Time target

Project Approach

  • Pathway mapping of each lung cancer service in Wiltshire and creation of Lucid charts depicting the current pathway
  • Gap analysis contributing towards co-creation of service re-design plans from gap analysis outputs for each site managing lung cancer patients in Wiltshire
  • Implementation of an optimised pathway for each site managing lung cancer patients across Wiltshire
  • Both parties commit to measuring the outcomes of the project and disseminating these outcomes within 6 months of the project completion

Benefits

Patient Benefits

  • An improved patient experience of the lung cancer pathway in Wiltshire
  • Quicker diagnosis and treatment of lung cancer and hence improving the chance of successful treatment

NHS Benefits

An optimised pathway in lung cancer across Wiltshire hospital sites resulting in

  • Achievement of the lung cancer 28 day Faster Diagnostic Standard, 31 day treatment target and 62 day referral to treatment target
  • Earlier referral, diagnosis and treatment of lung cancer patients
  • Increase in treatment rates for lung cancer
  • Optimisation of service delivery

MSD Benefits

  • Better understanding of lung cancer patient needs
  • Enhanced reputation of MSD through partnership work
  • As a pharmaceutical manufacturer of oncology medicines, an indirect result of an improved pathway may be that MSD see more appropriate usage of their NICE/SMC approved medicines

Funding

Total Project = £7,965; MSD contribution = £3,700; NHS Contribution =£4,265

 

Job Code GB-NON-05372 Date of Preparation – December 2021


University Hospitals Dorset NHS FT Poole General Hospital Lung Pathway Development Project (PDP)

Project Title

University Hospitals Dorset NHS FT Poole General Hospital Lung Pathway Development Project (PDP)

Organisations involved

MSD

University Hospitals Dorset NHS FT Poole General Hospital

Summary

A national optimal lung cancer pathway has been created with the intention of improving patient experience through promoting quality cancer care and ensuring all lung cancer patients receive optimal cancer care. There is an opportunity in and across Dorset to optimise the lung cancer pathway in line with the national optimal lung cancer pathway to improve the service quality, service efficiency, productivity and patient experience. The desired outcome of this project is an improved lung cancer pathway aligned with the national optimal pathway and achievement of the lung cancer 28 day Faster Diagnostic Standard and the 31 and 62 day Cancer Waiting Time Targets. The project intends to begin on 1st June 2021 and anticipates a finish date on 30th April 2022

Project Objectives

The primary objective of this project is the optimisation of lung cancer pathways across Dorset. Specifically contributing towards; –

  • An optimised lung cancer pathway aligned to the national optimal timed lung cancer pathway
  • Achievement of the lung cancer 28 day Faster Diagnostic Standard, 31-day treatment target and 62-day referral to treatment Cancer Waiting Time targets

Project Approach

  • Pathway mapping of each lung cancer service in Dorset and creation of Lucid charts depicting the current pathway
  • Gap analysis contributing towards co-creation of service re-design plans from gap analysis outputs for each site managing lung cancer patients in Dorset
  • Implementation of an optimised pathway for each site managing lung cancer patients across Dorset
  • Both parties commit to measuring the outcomes of the project and disseminating these outcomes within 6 months of the project completion

Benefits

Patient Benefits

  • An improved patient experience of the lung cancer pathway in
  • Quicker diagnosis and treatment of lung cancer and hence improving the chance of successful treatment

NHS Benefits

An optimised pathway in lung cancer across Dorset hospital sites resulting in

  • Achievement of the lung cancer 28 day Faster Diagnostic Standard, 31-day treatment target and 62-day referral to treatment Cancer Waiting Time targets
  • Earlier referral, diagnosis and treatment of lung cancer patients
  • Increase in treatment rates for lung cancer
  • Optimisation of service delivery

MSD Benefits

  • Better understanding of lung cancer patient needs
  • Enhanced reputation of MSD through partnership work
  • As a pharmaceutical manufacturer of oncology medicines, an indirect result of an improved pathway may be that MSD see more appropriate usage of their NICE/SMC approved medicines

Funding

Total Project = £14,190 MSD contribution = £7,300 NHS Contribution = £ 6,890

 

Job Code GB-NON-05406. Date of Preparation – December 2021


South Yorkshire and Bassetlaw Cancer Alliance Head & Neck Pathway Development Project (PDP)

Project Title

South Yorkshire and Bassetlaw Cancer Alliance Head and Neck Pathway Development Project (PDP)

Organisations involved

MSD

South Yorkshire and Bassetlaw Cancer Alliance:

  • Sheffield Teaching NHS Foundation Trust
  • Barnsley Hospital NHS Foundation Trust
  • The Rotherham NHS Foundation Trust
  • Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust
  • Chesterfield Royal Hospital NHS Foundation Trust

Summary

A national optimal Head and Neck Cancer pathway has been created with the intention of improving patient experience through promoting quality cancer care and ensuring all Head and Neck cancer patients receive optimal cancer care. There is an opportunity in South Yorkshire to optimise the Head and Neck cancer pathways in line with the national optimal Head and Neck cancer pathway to improve the service quality, service efficiency, productivity and patient experience. The desired outcome of this project is an improved Head and Neck cancer pathway aligned with the national optimal pathway and achievement of the Head and Neck cancer 28 day Faster Diagnostic Standard and the 31 and 62 day Cancer Waiting Time Targets. The project intends to begin on 1st January 2022 and anticipates a finish date on 31st December 2022

Project Objectives

The primary objective of this project is the optimisation of Head and Neck cancer pathways across South Yorkshire. Specifically contributing towards; –

  • An optimised Head and Neck pathway, aligned to the National Optimal Timed Head and Neck cancer pathway
  • Achievement of the Head and Neck 28 day Faster Diagnostic Standard, 31-day treatment target and 62 day referral to treatment Cancer Waiting Time target

Project Approach

  • Pathway mapping of each Head and Neck cancer service in South Yorkshire and creation of Lucid charts depicting the current pathway
  • Gap analysis contributing towards co-creation of service re-design plans from gap analysis outputs for each site managing Head and Neck cancer patients in the South Yorkshire
  • Implementation of an optimised pathway for each site managing Head and Neck cancer patients across the South Yorkshire
  • Both parties commit to measuring the outcomes of the project and disseminating these outcomes within 6 months of the project completion

Benefits

Patient Benefits

  • An improved patient experience of the Head and Neck cancer pathway in South Yorkshire
  • Quicker diagnosis and treatment of Head and Neck cancer and hence improving the chance of successful treatment

NHS Benefits

An optimised pathway in Head and Neck cancer across South Yorkshire hospital sites resulting in

  • Achievement of the Head and Neck cancer 28 day Faster Diagnostic Standard, 31-day treatment target and 62 day referral to treatment target
  • Earlier referral, diagnosis and treatment of Head and Neck Cancer patients
  • Increase in treatment rates for Head and Neck cancer
  • Optimisation of service delivery

MSD Benefits

  • Better understanding of Head and Neck cancer patient needs
  • Enhanced reputation of MSD through partnership work
  • As a pharmaceutical manufacturer of oncology medicines, an indirect result of an improved pathway may be that MSD see more appropriate usage of their NICE approved medicines

Funding

Total Project = £22,295.35           MSD contribution = £18,100  NHS Contribution =£4,195.35

 

Job Code GB-NON-05364. Date of Preparation – December 2021


Northern Cancer Alliance Head & Neck Pathway Development Project (PDP)

Project Title

Northern Cancer Alliance Head and Neck Pathway Development Project (PDP)

Organisations Involved

MSD
Northern Cancer Alliance:
North Cumbria Integrated Care NHS Trust
Newcastle upon Tyne NHS Foundation Trust
County Durham and Darlington NHS Foundation Trust
South Tyneside and Sunderland NHS Foundation Trust
South Tees NHS Foundation Trust

Summary

A national optimal Head and Neck Cancer pathway has been created with the intention of improving patient experience through promoting quality cancer care and ensuring all Head and Neck cancer patients receive optimal cancer care. There is an opportunity in the North East and North Cumbria to optimise the Head and Neck cancer pathways in line with the national optimal Head and Neck cancer pathway to improve the service quality, service efficiency, productivity and patient experience. The desired outcome of this project is an improved Head and Neck cancer pathway aligned with the national optimal pathway and achievement of the Head and Neck cancer 28 day Faster Diagnostic Standard and the 31 and 62 day Cancer Waiting Time Targets. The project intends to begin on 1st January 2022 and anticipates a finish date on 31st December 2022

Project Objectives

The primary objective of this project is the optimisation of Head and Neck cancer pathways across North East and North Cumbria.
Specifically contributing towards; –
• An optimised Head and Neck pathway, aligned to the National Optimal Timed Head and Neck cancer pathway
• Achievement of the Head and Neck 28 day Faster Diagnostic Standard, 31-day treatment target and 62 day referral to treatment Cancer Waiting Time target

Project Approach

• Pathway mapping of each Head and Neck cancer service in North East and North Cumbria and creation of Lucid charts depicting the current pathway
• Gap analysis contributing towards co-creation of service re-design plans from gap analysis outputs for each site managing Head and Neck cancer patients in the North East and North Cumbria
• Implementation of an optimised pathway for each site managing Head and Neck cancer patients across the North East and North Cumbria
• Both parties commit to measuring the outcomes of the project and disseminating these outcomes within 6 months of the project completion

Benefits

Patient Benefits

• An improved patient experience of the Head and Neck cancer pathway in the North East and North Cumbria.
• Quicker diagnosis and treatment of Head and Neck cancer and hence improving the chance of successful treatment

NHS Benefits

An optimised pathway in Head and Neck cancer across the North East and North Cumbria hospital sites resulting in
• Achievement of the Head and Neck cancer 28 day Faster Diagnostic Standard, 31-day treatment target and 62 day referral to treatment target
• Earlier referral, diagnosis and treatment of Head and Neck Cancer patients
• Increase in treatment rates for Head and Neck cancer
• Optimisation of service delivery

MSD Benefits

• Better understanding of Head and Neck cancer patient needs
• Enhanced reputation of MSD through partnership work
• As a pharmaceutical manufacturer of oncology medicines, an indirect result of an improved pathway may be that MSD see more appropriate usage of their NICE approved medicines

Funding

Total Project = £28,505.80 MSD contribution = £18,100 NHS Contribution =£10,405.80

Job Code GB-NON-05360. Date of Preparation – December 2021


Peninsula Cancer Alliance Lung Cancer Pathway Development Project (PDP)

Project Title

Peninsula Cancer Alliance Lung Cancer Pathway Development Project  (PDP)

Organisations involved

MSD
Peninsula Cancer Alliance; Royal Devon & Exeter Hospital; University Hospital Plymouth; North Devon Hospital; Royal Cornwall Hospital and Torbay & South Devon Hospital

Summary

A national optimal lung cancer pathway has been created with the intention of improving patient experience through promoting quality cancer care and ensuring all lung cancer patients receive optimal cancer care. There is an opportunity in Devon and Cornwall to optimise the lung cancer pathway in line with the national optimal lung cancer pathway to improve the service quality, service efficiency, productivity and patient experience. The desired outcome of this project is an improved lung cancer pathway aligned with the national optimal pathway and achievement of the lung cancer 28 day Faster Diagnostic Standard and the 31 and 62 day Cancer Waiting Time Targets. The project intends to begin on 3rd January 2022 and anticipates a finish date on 30th November 2022

Project Objectives

The primary objective of this project is the optimisation of lung cancer pathways across Devon and Cornwall. Specifically contributing towards; –

• An optimised lung cancer pathway, aligned to the national optimal timed lung cancer pathway
• Achievement of the lung cancer 28 day Faster Diagnostic Standard, 31-day treatment target and 62 day referral to treatment Cancer Waiting Time target

Project Approach

• Pathway mapping of each lung cancer service in Devon and Cornwall and creation of Lucid charts depicting the current pathway
• Gap analysis contributing towards co-creation of service re-design plans from gap analysis outputs for each site managing lung cancer patients in Devon and Cornwall
• Implementation of an optimised pathway for each site managing lung cancer patients across Devon and Cornwall
• Both parties commit to measuring the outcomes of the project and disseminating these outcomes within 6 months of the project completion

Benefits

Patient Benefits

• An improved patient experience of the lung cancer pathway in Devon and Cornwall.
• Quicker diagnosis and treatment of lung cancer and hence improving the chance of successful treatment

NHS Benefits

An optimised pathway in lung cancer across Devon and Cornwall hospital sites resulting in

• Achievement of the lung cancer 28 day Faster Diagnostic Standard, 31 day treatment target and 62 day referral to treatment target
• Earlier referral, diagnosis and treatment of lung cancer patients
• Increase in treatment rates for lung cancer
• Optimisation of service delivery

MSD Benefits

• Better understanding of lung cancer patient needs
• Enhanced reputation of MSD through partnership work
• As a pharmaceutical manufacturer of oncology medicines, an indirect result of an improved pathway may be that MSD see more appropriate usage of their NICE/SMC approved medicines

Funding

Total Project = £16,457; MSD contribution = £10,300; NHS Contribution = £6,157

 

Job Code GB-NON-06229. Date of Preparation – July 2022


Joint Working Projects

Gloucestershire AHP Prehabilitation Service (GAPS) for Lung Cancer Patients

Project Title

Gloucestershire AHP Prehabilitation Service (GAPS) for Lung Cancer Patients

Organisations involved

Gloucestershire Hospitals NHS Foundation Trust (GHNHSFT) and MSD

Summary

Gloucestershire Hospitals NHS Foundation Trust will work with MSD to set up, run and evaluate a Prehabilitation Service for lung cancer patients. The project will run for 6 months over which we will evaluate the extent to which prehabilitation services for lung cancer patients can support patient fitness levels throughout their pathway. We will measure any improvement or maintenance of patient fitness levels from the point at which they are referred into the lung cancer service, through to their treatment. We will also use the evaluation to inform a business case that will seek to ensure recurrent funding and sustainability of this service.

Background

While a lung cancer patient waits for their diagnosis and treatment, their performance status (as a measure of their fitness level) may decline meaning that their choice of treatment is sub-optimal, and they experience poorer outcomes. There is evidence for prehabilitation enhancing a cancer patients’ fitness and resilience for surgery, but little work has been done looking at patient’s fitness levels being maintained for SACT.

Project Approach

Through the running of GAPS we intend to provide a point of referral at the patient’s 2 week wait outpatient appointment. Their engagement with GAPS will run in parallel to their lung cancer pathway and will provide a series of interventions focussed around the physical and mental wellbeing of the patient. The service will be delivered by a team of Allied Health Professionals and include a Dietician, Physiotherapist, Exercise Trainer, Psychological Support and Occupational Therapist. The project will measure the uptake of the service and the impact that engaging in the service has on the patients physical and mental wellbeing.

Project Objectives

The service will be available for all patients who are referred to GHNHSFT with suspected lung cancer and are not known to be rapidly deteriorating or approaching end of life. Based on GHNHSFT 2020 figures, we would expect the number of patients accessing the service to be in the region of 150 across the 6-month period. The scope of the MSD service evaluation is to measure the change in PS and patient suitability for SACT. The wider scope of the lung prehabilitation service is to measure the change in PS for all patients that are referred into the lung cancer pathway, irrespective of route, stage, and of what type of treatment they ultimately receive. The objective of the service will be to;

  • Maintain or improvement fitness levels
  • Improve nutrition and reduce weight loss
  • Increase mental health resilience
  • Reduce patient anxiety
  • Sign posting to smoking cessation
  • Increase treatment rates for lung cancer
  • Demonstrate evidence for business case
  • Submit business case to gain recurrent funding for the sustainable running of the service

Benefits

Benefits to the Patient

  • Improved long term functional outcome
  • Enhanced disease management
  • Improved access to healthcare provision
  • Reduction in health inequalities
  • Potential improvement in patient’s fitness and wellbeing which may improve access to therapeutic options

Benefits to GHNHSFT

  • Shortened hospital length of stay
  • Reduced health costs in medications and follow up appointments
  • Potentially scalable prehabilitation service for patients with lung cancer that could be transferred to other cancer centres across the UK
  • Reduction in health inequalities
  • Potential cost savings and improved capacity
  • Potential opportunity to offer more therapeutic options to previously untreatable patients

Benefits to MSD

  • Opportunity for MSD to develop evidence to establish the benefit of prehabilitation to lung cancer patients to increase their available treatment options
  • Opportunity to engage as a partner with NHS Gloucestershire rather than just being seen as a supplier of medicines to the healthcare system
  • Potentially scalable service that could be shared with other cancer centres across the UK

Funding

This project involves a pooling of skills and resources between the GHNHSFT and MSD UK over 6 months.

MSD Contribution = £38,969; NHS Contribution = £33,632; Total Project = £72,601

Date of Preparation: March 2021 | GB-NON-03921


Manchester University NHS Foundation Trust Patient Experience App

Project Title

Manchester University NHS Foundation Trust Patient Experience App

Organisations involved

Manchester University NHS Foundation Trust

Summary

Wythenshawe Hospital (Manchester University NHS Foundation Trust) have initiated a RAPID (rapid access to pulmonary intervention and diagnosis) pathway for all lung cancer patients. It aims to reduce the time from GP referral to first treatment to 28 days, less than half the current NHS target. While the pathway has demonstrated advantages in time to diagnosis, further evidence is needed to understand the impact of such a fast-track diagnosis on the patient experience. The aim of the project is to work with Manchester University NHS Foundation Trust to develop a patient experience survey. The purpose of the survey is to build an evidence base of what the experience of the patient is within this accelerated pathway, and to facilitate continuous improvement to the pathway through real time analysis.

Background

Wythenshawe hospital have introduced the RAPID program for lung cancer patients, with the aim of 28 day pathway from referral to treatment decision.

While the pathway has demonstrated advantages in time to diagnosis, further evidence is needed to understand the impact of such a fast-track diagnosis on the patient experience.

Currently, patient experience surveys have focused on patients who have been given a cancer diagnosis, this project will address this by gaining insights into all patients going through RAPID- regardless of the diagnosis

Project Approach

  • To develop a patient experience app to capture patient satisfaction with the optimal lung cancer pathway within Wythenshawe hospital
  • The tool will be co-produced with GM focus group
  • The survey will be offered to approximately 500 patients going through the optimal lung cancer pathway at Wythenshawe hospital during a twelve-month period
  • Data will be captured and collated, and results reviewed
  • Evaluation- App will be built to deliver reports providing data analysis at 3/6/9/12 months. Report will be owned by the NHS and they will give license to MSD to use it. Any publication of data will be approved by both parties

Project Objectives

To work with Wythenshawe hospital to evidence the patient experience whilst in the RAPID (Rapid access to pulmonary assessment and diagnosis) lung cancer pathway.

To share and disseminate that data with the wider lung cancer community, to support the implementation of the NOLCP (or other service improvements) in other Trusts.

Benefits

Benefits to patients:

  • For patients currently in RAPID pathway, their patient experience concerns will be identified and addressed
  • Addressing patient concerns will continuously improve and develop the service for subsequent patients
  • Adding patient experience data to outcome data may prove sufficiently compelling to lead to wider adoption of the pathway in other Trusts, in turn speeding up the pathway there and reducing variation across the NHS
  • More rapid diagnoses may improve treatment rates and outcomes for patients

Benefits to NHS:

  • Capturing this patient experience data will enable generation of data to demonstrate performance and delivery of the pathway (by monitoring dates of interventions etc.) by the Trust, which may be used for reporting and publication. This will enable them to assess the value of extending the RAPID pathway across wider GM
  • Continuously improve the service (e.g. highlighting areas of need or dissatisfaction)
  • Provide other hospitals and services evidence to form business cases to adopt the RADID pathway
  • Development of a patient experience survey that can be used to support future pathways and projects within the wider NHS, in multiple cancers

Benefits to MSD:

Data generated on the patient pathway and experience prior to treatment decision could be used by MSD for:

  • Policy and advocacy activities
  • Development of patient support materials
  • Advocacy for the RAPID pathway model
  • Reputational benefit from partnering on this high profile, innovative project
  • All benefits are non-financial and can potentially be realised from the first data read out from the survey
  • An opportunity to measure patient experience in other projects in GM and the wider NHS

Funding

People:

From MSD:

  • Project manager to attend monthly meetings with steering group, to support and review progress throughout 12-month pilot
  • Oncology franchise and medical to advise on the methodology and design of the survey and analytical methods

From the NHS partner:

  • Development of App with 3rd party provider
  • Identification of suitable patients to take part in the survey, and encouraging usage of survey in 500 plus patients
  • Attendance at monthly meetings with steering group

Funds

Total MSD £41,650

Total NHS £37,500

Total project=£79,150

Date of Preparation: August 2020 Re-approval August 2022 | GB-NON-03087


EPIC: Early Prehabilitation In Lung Cancer

Project Title

EPIC: Early Prehabilitation In Lung Cancer

Organisations involved

Edinburgh Cancer Centre, NHS Lothian and MSD

Summary

The Edinburgh Cancer Centre, NHS Lothian is working with MSD to understand the feasibility of utilising prehabilitation techniques in patients with advanced metastatic lung cancer with the overall aim of reducing symptom burden, improving patient fitness and increasing treatment rates for lung cancer.

Background

Lung cancer is the most common cancer in Scotland with more than 5,300 registrations in 2018 and it accounted for over 25% of all cancer deaths. Five year survival rates remain below 10% with almost 50% of patients being identified at stage 4 meaning that access to treatment can be limited and this is compounded by the fact that many patients have comorbidities and are frail which adds to the symptom burden.

An option to help support patients with advanced lung cancer is the use of prehabilitation which is the practice of enhancing a patient’s functional and psychological capacity before treatment commences. It focuses on three areas –

  • Nutrition
  • Physical activity
  • Psychological support

Several studies indicate that prehabilitation is safe, feasible and can be delivered alongside complex treatment pathways in different cancer sites including lung cancer. A growing number of national and international reports now recommend prehabilitation as part of cancer pathways but little work has been carried out looking at the impact of prehabilitation in patients with advanced lung cancer.

Project Objectives

The project will be based at St John’s Hospital, Livingston and will aim to include all appropriate patients with advanced lung cancer.

The principle objectives will be to –

  • Maximise patient fitness as they are investigated and start treatment for lung cancer
  • Reduce symptom burden
  • Improve nutrition and stop weight loss
  • Maintain or improve performance scores
  • Sign posting to psychological support and smoking cessation
  • Increase treatment rates for lung cancer

The project is a pilot that now will run for 30 months after a decision by both the Edinburgh Cancer Centre, NHS Lothian and MSD to extend the project to phase 2 after initial learnings from the project signalled that it may be beneficial for patient care. At the end of the project the model will be evaluated and may well be of interest to other health economies across Scotland and the UK.

Benefits

Benefit to Patients

  • Improved access to healthcare provision
  • Enhanced disease management
  • Potential improvement patient’s fitness and wellbeing which may allow access to therapeutic options
  • Reduction in health inequalities

Benefits to the NHS

  • Potentially scalable prehabilitation service for patients with advanced lung cancer that could be scaled to other cancer centres across Scotland/UK
  • Aligns with national and local cancer policy – Scottish Government, SCAN, NHS Lothian
  • Priority of national third sector organisations
  • Potential opportunity to offer more therapeutic options to previously untreatable patients
  • Reduction in health equalities
  • Potential cost savings and improved capacity

Benefits to MSD

  • Opportunity to engage as a partner with NHS Lothian/SCAN rather than just a supplier of medicines
  • Potentially scalable project that could be shared with other cancer centres across the UK
  • Priority of national third sector organisations

Funding

The project is being funded with equal allocation of resources to the project from Edinburgh Cancer Centre, NHS Lothian and MSD

Date of Preparation: November 2021 | GB-NON-05303


Completed projects

SIMP-L Social Isolation Management Programme - Lothian

Project Title

SIMP-L

Social Isolation Management Programme – Lothian

Organisations involved

NHS Lothian and MSD

Summary

NHS Lothian are working with MSD to develop and support two community link worker roles focused on working with the socially isolated elderly in the south west of Edinburgh with the primary aims of improving patients’ quality of life and improving primary care capacity. In light of the Covid-19 pandemic the Community Link Workers will use their knowledge and experience to act as virtual liaison between the socially isolated elderly and the health, social care and third sector.

Background

Social isolation has detrimental effects on health, having been identified as a risk factor for all-cause morbidity and mortality with outcomes comparable to smoking, obesity and high blood pressure.

The socially isolated elderly are especially at risk with significant increases in the rates of CVD and diabetes, poorer cancer survival rates and decreased resistance to infection.

The socially isolated elderly are also the significant users of GP and practice nurse appointments, with a Royal College of General Practitioners survey finding that 75% of GPs see between one and five people a day who have come in mainly because they are lonely.1

The Scottish Government has recognised the impact on health and service capacity that social isolation can cause and recently implemented a national consultation in this area and there have been several studies looking at ways in which to tackle this issue.

In studies link worker models have been shown to have significant benefits to both patients and primary care capacity as well as positive financial outcomes for the local health economy.

Project Objectives

The project proposal involves working with NHS Lothian and the Edinburgh Health and Social Care Partnership (EHSCP) to develop and support two community link worker roles focused on working with the socially isolated elderly in the south west of Edinburgh.

The project is a pilot run for 27 months now that an evaluation of the original 15 month project signalled positive outcomes for patients and the NHS in Scotland. If successful, the model will be evaluated and may well be of interest to other health economies across Scotland.

The Link Workers would focus on socially isolated over 65’s (over 55’s in steering group approved practices) with objectives of:

  • Working to prevent social isolation in at risk patients
  • Improving the health/quality of life of the socially isolated
  • Building community capacity so that there is a robust infrastructure to support the socially isolated
  • Upskilling primary care healthcare teams to help identify socially isolated patients and signpost those patients to the appropriate support
  • Reduce workload for GPs/PNs so that they can focus on healthcare management rather than dealing with social issues

Benefits

Benefit to Patients

  • Aim to be less socially isolated/lonely
  • Possible improved health/quality of life
  • Possible prevention of illness
  • Aim for an improved management of chronic illnesses
  • Aim for an improved service provision allowing patients to access healthcare more easily

Benefits to NHS Lothian

The project will aim to help to meet a number of the priorities from the Edinburgh Health and Social Care Strategic Plan 2016 – 2022 including:

  • Tackling inequalities
  • Prevention and early intervention in disease management
  • Ensuring a sustainable model of primary care
  • Improving care and support for frail older people
  • Improving outcomes for people living with long-term and multiple conditions
  • Improving the understanding of the strengths and needs of the local population
  • Living within our means

As well as potentially:

  • Improving GP/PN capacity
  • Reducing A&E admissions/delayed discharges
  • There may be a reduction in drug spend (antidepressants, pain medications) although may not be directly attributed to the project
  • Improving community capacity
  • Improving service provision over the South West Locality

Benefits to MSD

  • Support and reinforce MSD’s aim to be the healthcare company of choice in Scotland
  • Indirectly benefit MSD as a result of potential improvements in capacity and service design, meaning more patients may be identified and they may go on to be prescribed an MSD product where deemed clinically appropriate
  • Opportunity to engage as a partner with NHS Lothian rather than just a supplier of medicines
  • Reputational benefits would be immediate and long lasting and the financial benefits would start to develop as more patients had access to primary care services

Funding

The project is being funded with equal allocation of resources to the project from NHS Lothian and MSD.

References

  1. RCGP calls for social prescriber in every practice to tackle ‘epidemic of loneliness’ http://www.pulsetoday.co.uk/news/commissioning/commissioning-topics/prescribing/rcgpcalls- for-social-prescriber-in-every-practice-to-tackle-epidemic-ofloneliness/ 20036746.article Last accessed [December 19, 2018]

Date of Preparation: Aug 2022 | GB-NON-06279


Diabetes Informatics Project – NHS Warrington CCG

Project Title

Diabetes Informatics Project – NHS Warrington CCG

Organisations involved

NHS Warrington CCG and MSD

Summary

NHS Warrington CCG will work with MSD to improve the quality of their diabetes service by understanding the community’s needs better, working with the community to meet care needs earlier and by looking at new and innovative ways to help them address the challenges set out by the burden of diabetes and to standardise the approach across the practices involved

Background

In March 2018, Warrington CCG embarked on a 2 Year Change Management Programme to increase the number of diabetic patients receiving high quality care in the community and a reduction in the number of un-scheduled admissions to secondary care. Year 1 was supported in part by MSD via a Joint Working Change Management programme called Evidence into Practice. This project aims to build on the improvements observed in Year 1 and embed a sustainable model that will enable continued improvement and proactive care of diabetic patients in the community setting.

Project Approach

  • Diabetes Dashboard will provide all 26 practices with their baseline diabetes performance against project deliverables and will update to reflect changes throughout the year providing practices with a visual way to review their clinical care improvement trajectories.
  • MSD will deploy a suite of searches written by a third -party search writing company (VIPC) across all 26 practices in Warrington CCG. VIPC is an Information management and technology solution company that specialise in search writing for General Practice. VIPC will write a suite of searches for the two IT systems used across Warrington CCG; EMIS and TPP. The specific searches will be agreed in collaboration with Warrington CCG’s Clinical lead to ensure an effective transition from the Evidence into Practice suite of searches to the VIPC suite of searches.
    The list of searches will be clinically validated and signed-off by Warrington before implementation in practice and will appear in a format that visually displays the number of Patients the search pertains to and the % of Patients that may/may not benefit from a review. All 26 Practices will download the VIPC suite of searches application independently following communication from Warrington CCG. VIPC will support any download/functionality queries on a practice by practice basis.
  • The DSN’s and Practice team will review the suite of searches to effectively identify and manage their Diabetic Patients in the practice on an ongoing basis.
  • Patients identified for Structured Education will be referred into the service as per the local Pathway.
  • A project manager will be assigned from MSD and the programme will be facilitated by this project lead.
  • The DSNs will provide clinical education during practice visits and review agreed patient groups at practice level.
  • Practices will review their Diabetes dashboard every 3 months and provide an anonymised report to the CCG 4 times per year.
  • Warrington CCG will evaluate project outcomes and share this with MSD
  • Warrington CCG intend to secure funding for VIPC beyond the initial 12-month project as part of its long term sustainably plan.

Project Objectives

  • Provide high quality Clinical Care in the community
  • More Patients achieving all 3 NICE prescribed clinical targets
  • More Patients receiving all 8 Care processes
  • Deploy a suite of searches written by a 3rd-party search writing company across all 26 Practices
  • Raise awareness of performance in diabetes care at practice level
  • Practices to adopt a more proactive approach to diabetes management.
  • Reduction in diabetic un-scheduled admissions
  • Adherence to Warrington CCG local pathway and National Diabetes guidelines
  • More Patients attending the Structured education programme to improve patient engagement and self-care.

Benefits

Benefits to patients

  • Treatment closer to home
  • In the long-term a proactive approach aims to support a reduction in diabetes related complications, hospital admissions and improved life expectancy.
  • People with diabetes feel better supported by having a greater understanding of their condition and treatment options available to them – Warrington CCG to measure through Patient feedback survey.

Benefits to the NHS partner

  • Service delivered closer to home contributing to Warrington CCG’s aims.
  • HCP’s delivering diabetes care can provide the best support and care in the community.
  • In the long-term a proactive approach will support a reduction in diabetes related complications, improved adherence to care plans through self-management and reduced complications and hospital admissions

Benefits to MSD

  • Demonstrate MSD as trusted partner through deployment of skills & resources to support higher quality care for Diabetic patients.
  • Improved relationship with Warrington CCG.
  • Data – 6 months/12-month evaluation shared with MSD
  • Data – Outputs of the 2-year programme to be shared with MSD
  • Opportunity for MSD Medicines – may benefit MSD indirectly from changes in Clinical behaviour as National and local guidelines are implemented.

Funding

This project involves pooling of skills and resources between the NHS and MSD over 12 months.

NHS Contribution; £31,410. MSD Contribution; £13,200. Total project cost £44,610

Date of Preparation: January 2022 | GB-NON-05450


Over 65s Vaccination GP Cluster Project

Project Title

Over 65s Vaccination GP Cluster Project

Organisations involved

MSD and Afan GP Cluster, Swansea Bay University Health Board

Summary

The objective of the project is to increase access to the National Immunisation Programmes (NIP) applicable to the over 65 age cohort. This will be achieved through collaborating with General Practices in the Afan Cluster to increase the uptake of Flu, Shingles and Pneumococcal vaccinations in line with the respective NIP within eligible cohorts of patients across the cluster.

Background

Currently vaccination rates for shingles, pneumococcal disease and also flu are low across Wales. The creation of GP clusters across Wales was designed to allow GP surgeries to work together to achieve shared targets across patient care. Due to the resourcing issues and stretched services GP clusters have not been able to provide this cluster approach and demonstrate their potential within vaccination services.

Project Approach

This project aims to pilot the use of GP clusters to enhance vaccination services and patient uptake of these services. It is proposed that the increase in vaccination uptake will provide enough revenue through vaccination administration payments to allow this project approach to become sustainable and replicable in other geographical areas.

A partnership between MSD and the Afan cluster will enable collaboration around improving care, eligible patients will receive an increased access to vaccinations in line with Public Health Wales and the National Immunisation Programme (NIP). A remote triaging service and subsequent vaccine administration will be provided by one of the surgeries situated within the cluster (Rosedale Medical Practice) who operate some other cluster services under the name – GP Hub. This will be a 6 month service addressing 3 areas of vaccinations in the over 65 year olds. The project would focus on over 65s who are eligible to receive all 3 vaccinations thereby maximising the impact that the approach will have.

Project Objectives

The objective of this project is to increase vaccination rates amongst eligible patients for the three National Immunisation Programmes within scope.

Benefits

Patients

  • An increased number of patients will receive access to vaccinations in line with Public Health Wales and the NIP
  • Reduce the risk of associated complications of shingles, pneumonia and Flu

NHS

  • The benefits to the GP practices will be that the respective uptake of vaccinations within their service will increase
  • Reducing the incidence of associated disease within the NIP and the cost utilization to the NHS
  • Increasing focus on over-burdened services such as long term conditions clinics as resource will not be pulling from existing services e.g. Diabetes- COPD
  • Sustainability post MSD Exit from project – business plan with economic service benefits to take to Public Health Wales

MSD

  • As a vaccines manufacturer MSD may see an increase in the uptake of certain vaccinations that they produce in line with Public Health Wales policy and the NIP
  • There is an additional reputational benefit to be gained through working in collaboration with the NHS to improve outcomes for patients

Funding

The total project budget is £36,702.40. This is made up from a contribution of £21,550 by MSD and a contribution of £15,152.4 by the Afan cluster group (Swansea Bay University Health Board).

Date of Preparation: January 2022 | GB-PNX-00164


Cardiff and Vale University Health Board Diabetes Informatics Programme

Project Title

Cardiff and Vale University Health Board Diabetes Informatics Programme

Organisations involved

MSD and Cardiff and Vale University Health Board

Summary

Cardiff and Vale University Health Board will work with MSD to improve the quality of their diabetes service by understanding the community’s needs better, working with the community to meet care needs earlier and by looking at new and innovative ways to help them address the challenges set out by the burden of diabetes and to standardise the approach across the practices involved.

Background

General Practice and secondary care diabetes services within Cardiff and Vale University Health Board are working collaboratively to provide coordinated, high quality clinical care, in the community, offers a positive patient experience and improves patient outcomes.

Across Wales and Cardiff and Vale UHB, there is a variation in the percentage of people with diabetes receiving the 8 care processes and achieving the NICE 3 treatment targets.

Project Approach

  • Diabetes Dashboard will provide all 62 practices with their baseline diabetes performance against project deliverables and will update to reflect changes throughout the year.
  • All 62 Practices will review the Diabetes Dashboard with their community diabetologist or DSN in an ongoing basis to discuss progress against the specific deliverables.
  • MSD will deploy a suite of searches written by a third -party search writing company (VIPC) across all 62 Practices in Cardiff and Vale UHB. VIPC is an information management and technology solution company that specialise in search writing for General Practice. VIPC will write a suite of searches for the two IT systems across Cardiff and Vale UHB; EMIS and VISION. The specific searches will be constructed in collaboration between clinical leads within Cardiff and Vale UHB and ViPC to ensure an effective transition from the Evidence into Practice suite of searches to the VIPC suite of searches.
  • The list of searches will appear in a format that visually displays the number of patients the search pertains to and the % of patients that may/may not benefit from a review.
  • All 62 Practices will download the VIPC suite of searches application independently following communication from lead clinicians within Cardiff and Vale UHB. The searches will be clinically validated and signed-off by Cardiff before implementation in practice. VIPC will support any download/functionality queries on a practice by practice basis.
  • The community consultants, DSN’s and practice teams will review the suite of searches to effectively identify and manage their diabetic patients in the practice on an ongoing basis.
  • Patients identified for structured education will be referred into the service as per local Pathway.
  • A project manager will be assigned from MSD and the programme will be facilitated by this project lead.
  • The community consultants and DSN’s will support clinical education during practice visits and review agreed patients groups at practice level.
  • Cardiff and Vale UHB will evaluate project outcomes using National Diabetes Audit data and share this with MSD.

Project Objectives

  • Standardise and harmonise ways of working by implementing NICE NG28
  • More cost-effective care: Cost effective prescribing, fewer admissions with diabetes complications, reduction in referrals to diabetes services.
  • Greater patient access based on need.
  • Workforce transformation and stability.

Benefits

Benefit to Patient – Patients feel better supported to manage their condition by having a greater understanding of their condition and the treatment options available to them which supports self-management leading to improved management and a better quality of life.

Benefit to NHS – People delivering diabetes care are able to provide the best support and care possible for people with diabetes by implementing NG28 which will lead to improved patient management and a reduction in the cost burden of managing diabetes. This will support an improved quality of care; a reduction in diabetes related complications and improved self-management.

Benefit to MSD – Supporting Cardiff and Vale University Health Board to improve outcomes for diabetic patients will demonstrate MSD as a trusted partner through deployment of skills and resources to support and facilitate higher quality care for all appropriate patients. The collaboration may benefit MSD indirectly from changes in clinical behaviour as National Diabetes guidelines (NG28) is implemented locally.

Funding

The total project budget is £45,700.00. This is made up from a contribution of £13,200 by MSD and a contribution of £32,500 by Cardiff and Vale University Health Board.

Date of Preparation: January 2022 | GB-NON-05449


Hepatitis C (HCV) testing within existing Tuberculosis (TB) testing service for patients (local and immigrants) in Newham, London.

Project Title

Hepatitis C (HCV) testing within existing Tuberculosis (TB) testing service for patients (local and immigrants) in Newham, London.

Organisations involved

BARTS NHS Trust – NHS Operational Delivery Network (ODN) for HCV for NE London, St. Georges NHS Laboratories & MSD.

Summary

To improve access to HCV diagnostics for people who may be at risk of HCV in Newham. Secondly, to evaluate the potential for identifying an otherwise missed group of patients at risk of HCV infection. To have an impact on on-wards transmission and improve linkage to care within the Newham ODN.

Timing

6-month project (May 2019 – November 2019)

Background

HCV case finding in the Newham population: This population are already routinely tested for TB by blood test, not X- Ray. They could also be screened for HCV at the same time but currently this is not happening. Newham is unique when it comes to the levels of immigration and routine TB testing. This could be highly beneficial to HCV testing and patient care. The project will also provide evidence for elimination strategy.

Project Objectives

Overall Project Objective

To improve access to HCV diagnostics for people who may be at risk of HCV in Newham. Secondly, to evaluate the potential for identifying an otherwise missed group of patients at risk of HCV infection. To have an impact on on-wards transmission and improve linkage to care within the Newham ODN.

Objective 1: To deliver point of contact testing in conjunction with the funded TB testing service in Newham Borough, London

Objective 2: To evaluate and communicate the results of the pilot to establish the potential or need for upscaling nationally across England

Benefits

Patients:

  1. Supports active case finding in this high-risk population – aligns to elimination agenda
  2. Demonstrates a “one stop shop” approach to immigrant patients already engaged with the extant TB testing service, enabling access to simultaneous HCV testing. This is based on the observed behaviours of this group, i.e. immigrant patients do attend for TB screening but only about 20% engage with current HCV screening. However, of those testing positive, 90% are treated). The project could demonstrate an increase in the HCV screening by adding to the TB testing lab work, immigrants do attend screening for TB

NHS & Public Health:

  1. The TB nurse team at BARTS will pass on any HCV positive results directly to one point of contact within the HCV ODN (Hepatology Clinical Nurse Specialist). There is therefore no additional commissioning required for this element of the service
  2. Provide information to the CCGs and Public Health regarding the services they may be required to fund to support the elimination agenda – NICE has made a recommendation to routinely test for TB, this therefore has scalability potential with Public Health across the U.K. – using templates
  3. The findings will inform ODNs in London and nationally providing a template for effective case finding and onward referral and treatment
  4. The project will generate valuable data insights to enrich the knowledge and data available to plan effective HCV services and elimination strategies

MSD:

  1. MSD is currently one of three suppliers of NHSE approved HCV medication
  2. The project will generate valuable data insights to enrich the knowledge and data available to plan effective HCV services and elimination strategies in the context of the drive to engage with and support the NHS in attaining the WHO HCV elimination goals
  3. The project will provide MSD with the opportunity to participate in population health initiatives in HCV, with the aim to demonstrate MSD as a credible partner with PHE, NHSE, London ODN’s, Local Authorities and patient groups where applicable
  4. From an MSD elimination strategy perspective, it may provide an evidence base to support implementation of directional elimination strategies such as Peer support

Funding

BARTS NHS Trust Contribution £13,714, MSD Contribution £10,000. The MSD funding for this JW project is unrelated and separate to the NHSE HCV tender.

Date of Preparation: May 2019 | GB-NON-00765 Approved for continued use May 2021


Greater Manchester optimal lung cancer pathway project

Project Title

Greater Manchester optimal lung cancer pathway project

Organisations involved

MSD

Greater Manchester Cancer Alliance (GM Cancer) – North West Sector

Summary

GM Cancer have commissioned a regional optimal lung cancer pathway which aims to achieve a treatment decision within 14 days of referral and commencement of treatment within 28 days. The pathway is to be rolled out across all 4 sectors within Greater Manchester (GM).
The role of MSD in this project will be to provide a Project Manager who will facilitate mapping of local lung pathways with a view to implementing the Greater Manchester agreed 28-day lung pathway across the North West sector. This will allow optimisation of processes at a local level across the sector and develop evidence for any resource gap that is present.
By implementing the optimal diagnostic pathway across the North West Sector there will be predicted improvements in cancer outcomes, survival and patient experience in line with the GM Cancer 5-year plan.

Background

GM Cancer Alliance covers the entirety of Greater Manchester and Eastern Cheshire. One of the priorities for GM Cancer Alliance is lung cancer and it is aiming to reduce diagnostic pathway to 28 days. Lung cancer MDTs across Greater Manchester have been divided into 4 sectors. The North-West sector includes Salford Royal NHS Foundation Trust, Wrightington, Wigan and Leigh NHS Foundation Trust, and Royal Bolton Hospital.

Optimisation of Lung Cancer Pathway: GM Cancer have commissioned a regional optimal lung cancer pathway which aims to achieve a treatment decision within 14 days of referral and commencement of treatment within 28 days.

Project Approach

The role of MSD in this project will be to provide a Project Manager who will facilitate mapping of local lung pathways, document what resources and processes are currently utilised along the pathway, implement and pilot the GM agreed 28-day lung pathway across the North West sector. The aim is to allow optimisation of processes at a local level across the sector and develop evidence for any resource gap that is present.

Project Objectives

To deliver high quality, rapid and efficient diagnostic pathways, exceeding national standards, whilst reducing variation across the sector and ensuring all patients receive the highest level of care, comparable with the top performing trusts. The overall aim is to achieve the Regional Optimal Lung Cancer 28-day Pathway.

Benefits

Benefits to patients: Patient experience in the North West sector improves based on standardised pathway that reduces wait times and ensures patients receive equitable care in Greater Manchester.

Benefits to NHS: Recommended lung cancer pathway is provided to NHS stakeholders and improvements are made to decrease variation and increase pathway efficiency.

Benefits to MSD: Enhanced reputation of MSD and the wish to work with MSD further. MSD gains a better understanding of customer and patient needs.

Funding

From MSD:

  • 2 days per week project management
  • Estimated cost to project = £28,360

From the NHS partner:

  • 0.5 days per week from Project Lead, Oncology Consultant, Band 8C nurse, Various MDT & others
  • Estimated cost £27,504

Update September 2020: The project was put on hold for 6 months due to delays caused by COVID-19. It has been agreed to resume the project and extend to March 2021. There will be no additional costs or resources required, other than those agreed within the original PID for this project.

Date of Preparation: September 2020 | GB-NON-03269


Northern Cancer Alliance Lung Pathway Board Project

Project Title

Northern Cancer Alliance Lung Pathway Board Project

Organisations involved

Northern Cancer Alliance & MSD UK Ltd

Summary

The Northern Cancer Alliance want to establish a Lung Cancer Pathway Board. The aim of the Lung Cancer Pathway Board is to improve lung cancer care for patients in the North East and North Cumbria, delivering an integrated care pathway from presentation and diagnosis through to personalised and palliative care for lung cancer thus reducing inequalities and delivering improved outcomes.

Background

The Northern Cancer Alliance population is about 5.9% of the England population but has 6.5% of all malignancies and 8.2% of total lung cancers.1
For both males and females, lung cancer is the second most common cancer in the geographies across the Northern Cancer Alliance.1
Lung cancer is the most common cause of cancer death in England, accounting for almost 21% cancer deaths (2017).1
In the Northern Cancer Alliance, lung cancer deaths equate to 24.8% of cancer deaths.1

Project Approach

The role of MSD UK in this project will be to provide a project manager who will provide project management support to the Northern Cancer Alliance Lung Pathway board. The resource required and commitment to complete this project is a project manager for 2 days per week for 12 months.
The Northern Cancer Alliance will provide a clinical chair for the Lung Pathway Board, administrative support and clinical and management supervision for the duration of the project.

Project Objectives

The primary objective of the Lung Cancer Pathway Board is to ensure that every lung cancer patient has access to an equitable, effective and responsive service compliant with National and Local standards, including specific lung cancer waiting times, with the aim of improving outcomes to be in line with world class services. This will include:

  • Implementation of the National Optimal Lung Cancer Pathway (NOLCP)
  • Implementation of the 28-day Faster Diagnostic Standard (FDS) Timed Lung cancer pathway, addressing local variation and inequality
  • Dissemination and adoption of the North East Lung Case Finding Pilots (COPD annual review)
  • Streamlining of MDT meetings and developing standards of care for lung cancer pathway

Benefits

Patients

  • Earlier detection, diagnosis and treatment of lung cancer patients
  • Patients detected, diagnosed and treated at an earlier stage of lung cancer have a greater chance of successful treatment, greater survival rates and clinical outcomes
  • Improved patient experience of lung cancer pathway

NHS

  • Implementation of the National Optimal Lung Cancer Pathway
  • Achievement of lung cancer treatment targets (28-day target, 62 day target)
  • Increased percentage of lung cancer patients being diagnosed at stage 1+2 as per the NHS target of 75% by 2028
  • Earlier detection, diagnosis and treatment of lung cancer patients leads to more cost-effective use of healthcare resources and increased patient survival and patient experience

MSD

  • Increased understanding of the lung cancer pathway and the challenges and solutions to its successful implementation and improvement which can be shared both internally within MSD UK and externally with NHS stakeholders outside of the North East and North Cumbria
  • As a pharmaceutical manufacturer of oncology medicines, MSD may see an increase in usage of its NICE approved lung cancer medications as a result of this projects implementation of the National Optimal Lung Cancer Pathway
  • Enhanced reputation of MSD UK and the wish to work in partnership further
  • MSD UK gains a better understanding of customer and patient needs in lung cancer

Funding

This project involves a pooling of skills and resources between the Northern Cancer Alliance and MSD UK over 12 months.

MSD Contribution = £28,000

NHS Contribution = £36,000

Total Project = £64,000

Update September 2020: The project was put on hold for 3 months in 2020 due to delays caused by COVID-19. It has been agreed to extend the project to March 2021. There will be no further costs or resources required, other than those previously agreed in the initial PID for this project.

References –

  1. Data supplied by Northern Cancer Alliance

Date of Preparation: November 2020 | GB-NON-03702


SAS‐HYPO‐FIFE

Project Title

SAS‐HYPO‐FIFE

Organisations involved

Scottish Ambulance Service (SAS) and MSD

Summary

The Scottish Ambulance Service (SAS) are working with NHS Fife Diabetes Service with the support of SCI‐Diabetes and MSD to better manage hypoglycaemia in their diabetic patients with particular emphasis on what happens to patients who experience a hypoglycaemic event that results in an ambulance call‐out. The aim of the project is to improve patient care, increase capacity and upskill attending paramedics.

Background

Patients with diabetes can have their health affected in a number of ways and one of the most serious is when they experience a hypoglycaemic event. These events can be devastating and have a lasting and negative effect on the patient’s physical and mental health.

In addition to the impact of these hypoglycaemic events on patients, the impact on the health economy can be substantial.

Project Objectives

The project objectives are as follows ‐

  • Through an online questionnaire understand any knowledge gaps in diabetes management amongst SAS staff in NHS Fife
  • Identify “Station Leaders” at each paramedic base who will receive additional training in diabetes and leadership and that will be responsible for upskilling local paramedics
  • Develop an online training programme for SAS paramedics across Scotland hosted on the NHS Scotland learnPro platform
  • Analyse data from the project in areas such as ambulance call outs rates, A&E attendances, ambulance scene time, and conveyed versus non conveyed patients
  • Produce an evaluation of the project including learnings for the SAS, NHS Fife and MSD that will help shape the role out of the project across other healthboard areas in Scotland

Benefits

Benefit to Patients – Through the enhanced knowledge and confidence of local SAS staff attending to patients, the recording of information in a standardised way and the subsequent follow up by designated HCP’s, patients will have access to a better, more cohesive standard of care and it is anticipated will have better outcomes as a result.

Benefit to the SAS – The project will help to meet a number of the priorities from the SAS Local Delivery Plan 2017‐18 including–

  • Evidence a shift in the balance of care by taking more care to the patient in their homes
  • Enhance clinical skills as a key and integral partner working with primary and secondary care
  • Expand diagnostic capability and use of technology to improve patient care
  • There is potential for reducing demand on acute call outs for hypoglycaemic patients

Benefit to NHS – The project will help to meet a number of the priorities from the NHS Fife Local Delivery Plan 2017‐18 including –

  • Support people more effectively to remain well at home and where need for additional support is needed offer the most appropriate level of intervention possible.
  • Reduce the gap in health inequalities for those from socially deprived communities so that they experience parity in terms of access and outcomes.
  • Potential reduction in avoidable emergency department attendances
  • Potential reduction in avoidable admissions

Benefit to MSD

  • Support and reinforce MSD’s aim to be the healthcare company of choice in Scotland and MSD’s reputation as a trusted and valued partner will be enhanced
  • Healthcare professionals to re‐evaluate existing medication to help reduce hypoglycaemic events, which may be favourable to MSD and other manufacturers

Funding

This project involves a pooling of skills and resources between the SAS and MSD over 18 months

SAS contribution: £9800; MSD Contribution: £9900; Total £19700

Date of Preparation: August 2020 | GB-NON-03110


Derbyshire pharmacy testing initiative for hepatitis C and HIV

Project Title

Derbyshire pharmacy testing initiative for hepatitis C and HIV.

Organisations involved

MSD UK, Derbyshire LPC and Derbyshire County Council Public Health.

Summary

Aims: To determine if testing for hepatitis C and HIV in pharmacies delivering needle exchange and/or supervised consumption services can reduce the impact of on-wards transmission of hepatitis C and HIV and reduce the reinfection. This will be done by identifying infection hot spots and potential treatment networks to facilitate access to diagnosis and ensure transition into treatment for this vulnerable mobile population.

Methodology:
The results will be measured by the pharmacists and a report of the results shared with ODN’s, public health, LPC, commissioners and other interested stakeholders both locally and nationally.
The following will be measured and assessed: 1.) Pharmacist engagement and total number of tests undertaken; 2). No. of patients tested and counselled; 3.) No. and % of positive diagnoses; 4). % of patients referred into care; 5.) % of positive patients successfully following treatment pathway

Timing:
1.) Kick-off meeting (15/01/18); 2.) Pharmacists training meetings (Apr 2018); 3.) Pharmacy testing of hepatitis C and HIV (July – Nov 2018) and with phase 2 testing ( Mar- May 2019) ; 4.) Interim project results (Jul 2019); 5.) Data assessed and shared (PHE Registrar) by Sept 2019; 6.) Monthly project Review Meetings; 7.) Project outcomes and results communicated (Sep 2019)

Outcomes Expected:
1.) Increased engagement of both patients and pharmacists; 2.) Increase in referrals, diagnosis and treatment; 3.) Improved patient outcomes and reduce reinfection rate; 4.) Positive patient experience; 5.) Increased engagement between all stakeholders; 6.) CCGs to fund service longer term

Background

75% of needle exchanges are in pharmacies rather than within drug and alcohol treatment services. This is therefore an environment where current drug users are likely to attend and can be offered hepatitis C and HIV testing. Currently there is little or no hepatitis C or HIV testing undertaken at this first and regular point of contact. The project will also provide onward referral to assessment and treatment for patients who inject drugs (PWIDs) and especially people currently using drugs have found services difficult to access.

Project Approach

This is a Proof of Concept project that will support Derbyshire Public Health in the development of their strategy moving forward with regard to the sustainability of community based services. If successful, there is also the opportunity to recruit additional pharmacies to deliver the testing service outside of the pilot pharmacies subject to funding being made available via NHS or Public health. The evidence from this project will be shared to support other CCGs to obtain longer term financial commitment to fund the service. The project also intends to lead to an increase in engagement of patients and an increase of referrals. This in turn should lead to more diagnoses and an increase in treatment by identifying more patients requiring treatment.

Project Objectives

Patients: 1.) To receive point of contact testing in community pharmacies that offer needle exchange/ supervised consumption. 2.) For a positive screening test to have referral into appropriate treatment pathway.

NHS / LPC / Public Health: 1.) Identify barriers in the pathway of testing in the needle exchange, to accessing assessment and treatment through the Operational Deliver Network (ODN) Multi-Disciplinary Team (MDT). 2.) Provide information to the CCGs and Public Health regarding the services to support funding requirements. 3.) To provide a health economic guide for CCG’s local population.

MSD: 1.) Partner with the ODNs / secondary care regionally to identify novel pathways for both identification of the viral burden and developing strategies to best target resources. 2.) Determine if the model of treating drug user networks could be applied to the wider Derbyshire population and reduce transmission as indicated by research in Scotland.

Benefits

Patients: 1.) Provision of quick and easy access to testing and a clear pathway into assessment and treatment in specialist care. 2.) Increased engagement in testing service. 3.) Improved outcomes.

NHS : LPC and Public Health:1.) Provide information to the CCG’s and public health regarding the services they will be required to fund for longer term sustainability. 2.) Optimise the patient pathway to reduce the barriers of testing in the needle exchange and accessing assessment and treatment through the Operational Deliver Network (ODN) Multi-Disciplinary Team (MDT) Secondary care. 3.) The findings will inform ODN’s regionally and nationally, providing a template for effective case finding and onward referral and treatment.

MSD: 1.) MSD is currently a supplier of NHSE approved HCV and HIV medications and patients may have access to these treatments, however there will be no preferential arrangement in place over other available treatments. 2.) The project will provide a seat at the table for population health initiatives in HCV and allow MSD to strengthen relationships with PHE, NHSE, ODNs, the local authorities involved as well as patient group stakeholders. 3.) From a policy perspective, it will provide an evidence based proof of concept to support our thinking around the sustainability of HCV / HIV services.

Funding

Derbyshire LPC and Public Health are supporting the training of pharmacists, the delivery of the testing service, client testing fee and data capture including final write up for publication at a cost of £11,330. MSD are funding £10,479,72 which includes testing kits, screening analysis, clinical waste management and project management support. Following the completion of the project £5,719.09 was returned to MSD as unused funds.

Date of Preparation: March 2021 | GB-NON-04270